The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.

Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

Ocular toxicities could be the reason.

Adverse events will be closely watched when full data are reported.

A key pivotal study of bemarituzumab will read out shortly.